Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does CYCLOSPORINE Cause Second primary malignancy? 24 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 24 reports of Second primary malignancy have been filed in association with CYCLOSPORINE (Verkazia). This represents 0.0% of all adverse event reports for CYCLOSPORINE.

24
Reports of Second primary malignancy with CYCLOSPORINE
0.0%
of all CYCLOSPORINE reports
14
Deaths
7
Hospitalizations

How Dangerous Is Second primary malignancy From CYCLOSPORINE?

Of the 24 reports, 14 (58.3%) resulted in death, 7 (29.2%) required hospitalization, and 2 (8.3%) were considered life-threatening.

Is Second primary malignancy Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for CYCLOSPORINE. However, 24 reports have been filed with the FAERS database.

What Other Side Effects Does CYCLOSPORINE Cause?

Drug ineffective (11,172) Off label use (6,860) Eye irritation (5,806) Product use in unapproved indication (5,019) Condition aggravated (2,310) Eye pain (2,197) Drug intolerance (2,176) Pneumonia (2,022) Pyrexia (2,020) Treatment failure (1,961)

What Other Drugs Cause Second primary malignancy?

CYCLOPHOSPHAMIDE (1,247) DOXORUBICIN (1,151) VINCRISTINE (908) IMATINIB (763) PALBOCICLIB (658) RITUXIMAB (646) RUXOLITINIB (611) ETOPOSIDE (573) PREDNISONE (517) OCTREOTIDE (496)

Which CYCLOSPORINE Alternatives Have Lower Second primary malignancy Risk?

CYCLOSPORINE vs CYCLOSPORINE A CYCLOSPORINE vs CYMBALTA CYCLOSPORINE vs CYNODON DACTYLON POLLEN CYCLOSPORINE vs CYPROHEPTADINE CYCLOSPORINE vs CYPROTERONE

Related Pages

CYCLOSPORINE Full Profile All Second primary malignancy Reports All Drugs Causing Second primary malignancy CYCLOSPORINE Demographics